Literature DB >> 33246635

Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.

Stephen A Graves1, Robert F Hobbs2.   

Abstract

Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has benefitted patients by reducing the incidence of side effects and improving overall survival in populations treated under this paradigm. Development of tools and techniques for dosimetry-guided therapy is ongoing, with numerous the Food and Drug Administration-cleared products reaching the U.S. market in 2019. Safe use of commercial dosimetry platforms requires a deep understanding of the underlying physical principles and thoroughly vetted input data. Likewise, interpretation of dosimetry results relies on an understanding of radiobiological principles, and the principles of uncertainty propagation. In this article, we review strategies commonly employed for dosimetry-guided RPT - including quantitative imaging, dose calculation methods, and modeling of dose across time-points. Additionally, we review recent literature evidence (2013-2020) demonstrating the efficacy of personalized RPT.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33246635     DOI: 10.1016/j.semradonc.2020.07.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  2 in total

1.  Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.

Authors:  Ying Liu; Yuzhu Wang; Xinkun Guo; Yifeng He; Jian Zhou; Qianzhou Lv; Xiaowu Huang; Xiaoyu Li
Journal:  Front Oncol       Date:  2021-09-02       Impact factor: 6.244

Review 2.  Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.

Authors:  Kristin A Plichta; Stephen A Graves; John M Buatti
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.